TY - JOUR
T1 - 2018 annual dialysis data report of the JSDT Renal Data Registry
T2 - patients with hepatitis
AU - on behalf of the Japanese Society for Dialysis Therapy Renal Data Registry Committee
AU - Nitta, Kosaku
AU - Nakai, Shigeru
AU - Masakane, Ikuto
AU - Hanafusa, Norio
AU - Goto, Shunsuke
AU - Taniguchi, Masatomo
AU - Hasegawa, Takeshi
AU - Wada, Atsushi
AU - Hamano, Takayuki
AU - Hoshino, Junichi
AU - Joki, Nobuhiko
AU - Yamamoto, Keichi
AU - Miura, Kenichiro
AU - Abe, Masanori
AU - Nakamoto, Hidetomo
AU - Maeno, Kazuyuki
AU - Kawata, Tetsuya
AU - Oyama, Chikara
AU - Seino, Koji
AU - Sato, Toshinobu
AU - Sato, Shigeru
AU - Ito, Minoru
AU - Kazama, Junichiro
AU - Ueda, Atsushi
AU - Saito, Osamu
AU - Ando, Tetsuo
AU - Ogawa, Tomonari
AU - Kumagai, Hiroo
AU - Terawaki, Hiroyuki
AU - Ando, Ryoichi
AU - Abe, Masaki
AU - Kashiwagi, Tetsuya
AU - Hamada, Chieko
AU - Shibagaki, Yugo
AU - Hirawa, Nobuhito
AU - Shimada, Hisaki
AU - Ishida, Yoichi
AU - Yokoyama, Hitoshi
AU - Miyazaki, Ryoichi
AU - Fukasawa, Mizuya
AU - Kamijyo, Yuji
AU - Matsuoka, Teppei
AU - Kato, Akihiko
AU - Mori, Noriko
AU - Ito, Yasuhiko
AU - Kasuga, Hirotake
AU - Koyabu, Sukenari
AU - Arimura, Tetsuro
AU - Hashimoto, Tetsuya
AU - Inaba, Masaaki
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Abstract: According to the annual survey of the Japanese Society for Dialysis Therapy Renal Data Registry (JRDR) conducted at the end of 2018, a total of 339,841 patients were receiving dialysis (hereinafter, dialysis patients) in Japan. This survey included an investigation of individual test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody (HCV-Ab), HCV-RNA, and serum alanine aminotransferase (ALT) (glutamic pyruvic transaminase [GPT]). The survey revealed that among dialysis patients in Japan, the prevalence of HBsAg positivity was 1.38% and the prevalence of HCV-Ab positivity was 4.7% at the end of 2018, both of which were markedly lower than the corresponding rates documented in 2007 (9.8% and 4.7%, respectively). The proportion of HCV-RNA-positive patients among all HCV-Ab-positive patients was 37.5%, which was also markedly lower than the percentage recorded in 2007 (64.0%). The prevalence of HBsAg positivity tended to increase as the dialysis vintage increased. The prevalence of HCV-Ab positivity was also not correlated with the dialysis vintage during the first 30 years of dialysis; however, it tended to increase as the dialysis vintage increased beyond the 30th year. Trial registration: University hospital Medical Information Network (UMIN) Clinical Trials Registry, UMIN000018641. The JRDR was approved by the ethics committee of the JSDT (approval number 1-3) and was registered on August 8, 2015 (accessed June 2, 2020).
AB - Abstract: According to the annual survey of the Japanese Society for Dialysis Therapy Renal Data Registry (JRDR) conducted at the end of 2018, a total of 339,841 patients were receiving dialysis (hereinafter, dialysis patients) in Japan. This survey included an investigation of individual test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody (HCV-Ab), HCV-RNA, and serum alanine aminotransferase (ALT) (glutamic pyruvic transaminase [GPT]). The survey revealed that among dialysis patients in Japan, the prevalence of HBsAg positivity was 1.38% and the prevalence of HCV-Ab positivity was 4.7% at the end of 2018, both of which were markedly lower than the corresponding rates documented in 2007 (9.8% and 4.7%, respectively). The proportion of HCV-RNA-positive patients among all HCV-Ab-positive patients was 37.5%, which was also markedly lower than the percentage recorded in 2007 (64.0%). The prevalence of HBsAg positivity tended to increase as the dialysis vintage increased. The prevalence of HCV-Ab positivity was also not correlated with the dialysis vintage during the first 30 years of dialysis; however, it tended to increase as the dialysis vintage increased beyond the 30th year. Trial registration: University hospital Medical Information Network (UMIN) Clinical Trials Registry, UMIN000018641. The JRDR was approved by the ethics committee of the JSDT (approval number 1-3) and was registered on August 8, 2015 (accessed June 2, 2020).
KW - Dialysis
KW - Hepatitis
KW - Prevalence
KW - Registry
UR - http://www.scopus.com/inward/record.url?scp=85105711525&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105711525&partnerID=8YFLogxK
U2 - 10.1186/s41100-021-00338-8
DO - 10.1186/s41100-021-00338-8
M3 - Article
AN - SCOPUS:85105711525
SN - 2059-1381
VL - 7
JO - Renal Replacement Therapy
JF - Renal Replacement Therapy
IS - 1
M1 - 22
ER -